Overview

Modeling Center of Excellence Practices to Improve the Care of Patients With Biomarker-Driven Thyroid Cancer or Non-Small-Cell Lung Cancer

Registration is closed for this activity.

Format

Point-of-Care Learning

Time to Complete

1.00 hr(s).

Date

Wednesday, September 18, 2024 12:00 PM ET

Location

Roswell, GA

Targeted therapies are driving a rapidly evolving landscape in cancer care. Are your molecular testing procedures optimized to guide treatment for your patients diagnosed with NSCLC or thyroid cancer? Are you using the right tests at the right times for the right patients? Assess your current practices and procedures, and create a plan to optimize testing and treatment, through this innovative, customized, point-of-care learning program designed to help you enhance your processes and improve your ability to implement the most appropriate biomarkers and assays to inform treatment selection. Collaborate with expert faculty to develop strategies to overcome the barriers you face and better individualize therapy according to molecular testing results to improve outcomes for your patients with thyroid cancer or NSCLC. Join your colleagues in this new frontier of personalized medicine today!

This activity is intended for intended for oncologists, pathologists and the multidisciplinary team practicing in academic and community settings, including oncology pharmacists who treat patients with NSCLC or thyroid cancer.

The identification of targetable tumor-specific molecular alterations has grown rapidly, leading to the application of precision medicine in oncology. Recently, therapies targeting receptor tyrosine kinase RET (rearranged during transfection) gene alterations have been developed for the treatment of multiple malignancies, including NSCLC and thyroid cancers. Although testing for RET alterations is recommended, such testing is underutilized in clinical practice, leading to suboptimal treatment selection. Indeed, surveys have found that 60% of oncologists made first line treatment decisions for patients with NSCLC prior to a review of molecular testing results. Moreover, a wide variance among institutions has been found in the utilization of molecular testing procedures, stemming from several factors including delays in physician orders (vs reflex testing), collection of tissue samples that are adequate for biopsies but inadequate for molecular testing, and test turnaround time.

Therefore, education on optimal molecular testing strategies and treatment selection, and development of strategies to overcome testing challenges, are vital for improving patient care. The promise of precision medicine rests in the collaborative team of pathologists and oncologists and the integration of molecular testing to optimize treatment of patients diagnosed with NSCLC or thyroid cancer. This program will provide practical guidance for improving clinical ability to follow guideline recommendations for identifying the most appropriate molecular tests, as well increasing proficiency in applying testing results to treatment selection. In addition, through discussion and collaboration with experts, this program will aid institutions in developing strategies to overcome testing barriers and improve protocols and workflows to enhance clinical practices and improve patient outcomes.

Upon completion of this activity, learners will be able to:

Develop improved models for early and effective biomarker testing

Identify appropriate patients and optimize treatment for RET-targeted therapy

Develop strategies to mitigate challenges and barriers to optimizing RET testing for patients with NSCLC and thyroid cancer

Upon completion of this activity, pharmacists will be able to:

• Describe how pharmacist expertise in pharmacology and its clinical applications enhance precision oncology care and access to targeted therapies

• Develop pharmacy-led strategies to mitigate challenges and barriers to optimizing RET testing for patients with NSCLC and thyroid cancer

Wellstar North Fulton Hospital
Roswell, GA USA
Click here to view location map

This activity is supported by an educational grant from Lilly.

Maria Arcila, MD
Attending Pathologist and Laboratory Director, Diagnostic Molecular Pathology
Medical Director, Molecular Hematopathology
Memorial Sloan Kettering Cancer Center
New York, NY

Marcia Brose, MD, PhD, FASCO

Director, Cancer Services

Vice Chair, Hematology and Medical Oncology

Co-Director Community Based Clinical Trials

Sidney Kimmel Cancer Center - Jefferson Health

Philadelphia, PA

Lori Wirth, MD

Associate Professor

Harvard Medical School

Medical Director

Massachusetts General Hospital’s Center for Head and Neck Cancers

Boston, MA

Christine Bestvina, MD (Content Reviewer)

Associate Professor

Department of Medicine, Section of Hematology/Oncology

University of Chicago Medicine

Chicago, IL

The University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL) require that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

The following financial relationships have been provided:

Maria Arcila, MD

Consultant: AstraZeneca, Bristol-Myers Squibb, Janssen Global Services, and Roche Diagnostics

Advisory Board: Biocartis Global

Marcia Brose, MD, PhD, FASCO

Consultant: Bayer, Eisai Co., Ltd., Exelixis, Inc., Lilly

Honorarium recipient: Eisai Co., Ltd.

Lori Wirth, MD

Consultant/Advisor: AbbVie, Bayer, Coherus, Eli Lilly, Eisai, EMD Serono, Exelixis, Genentech

Strategic Council Member: Galera Therapeutics

Scientific Advisory Committee: Ellipses

Data and Safety Monitoring Committee (DSMC) Member: PDS Biotechnology

Christine Bestvina, MD (Content Reviewer)

Grants/Research Support: AstraZeneca, Bristol Myers Squibb

Consultant: AstraZeneca, Bristol Myers Squibb, CVS, Daiichi Sankyo, EMD Sereono, Gilead, Mirati, Novocure, Regeneron, Sanofi, Takeda, Tempus

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Pralsetinib is not approved for the treatment of advanced/metastatic dedullary thryroid cancer

University of Chicago staff members, ACHL staff members, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. The University of Chicago and ACHL require the speaker to disclose that a product is not labeled for the use under discussion.

This activity will take approximately 60 minutes to complete. To receive credit, learners are required to participate in the live activity and complete the posttest and evaluation onsite or online following the education. A certificate will be immediately available upon completion of the surveys. There is no fee to participate in the activity or for the generation of the certificate. For questions, contact Karen Catino at kcatino@achlcme.org.

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This activity has been approved for 1.0 contact hours.

ACPE Universal Activity Number: 0396-9999-24-024-L01-P

Activity Type: Application

CPE credit will be submitted to CPE Monitor® on the first business day of each month.

McKenna Reinhard
mreinhard@achlcme.org
Phone: (773)714-0705 ext. 121

Overview

Modeling Center of Excellence Practices to Improve the Care of Patients With Biomarker-Driven Thyroid Cancer or Non-Small-Cell Lung Cancer

Program Description

Intended Audience

Activity Purpose

Learning Objectives

Activity Location

Supporter Information

Faculty

Faculty Disclosure

Staff Disclosure

Disclaimer

Method of Participation

Accreditation and Credit Designation

Program Manager

Related Activities